ARTICLE | Company News
Tokai cancer news
August 15, 2016 7:00 AM UTC
Tokai will reduce headcount by about 15 (60%) to 10 after it discontinued in July the Phase III ARMOR3-SV trial of galeterone ( TOK-001) to treat metastatic castration-resistant prostate cancer (CRPC)...